| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 5.165 | 57.577 | 8.915 | 19.749 | 35.700 | 20.271 | 25.230 | 47.090 | 52.726 | 57.465 |
| Total Income - EUR | 5.165 | 57.577 | 8.915 | 19.749 | 35.700 | 20.271 | 25.230 | 47.090 | 52.726 | 57.466 |
| Total Expenses - EUR | 463 | 11.598 | 5.627 | 5.637 | 9.454 | 3.526 | 5.069 | 14.748 | 27.312 | 36.311 |
| Gross Profit/Loss - EUR | 4.702 | 45.980 | 3.288 | 14.112 | 26.246 | 16.745 | 20.161 | 32.342 | 25.414 | 21.155 |
| Net Profit/Loss - EUR | 4.547 | 44.252 | 3.021 | 13.520 | 25.175 | 16.219 | 19.924 | 30.929 | 24.887 | 20.592 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Meditib Ig-Test S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 110 | 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 4.683 | 49.417 | 5.587 | 18.704 | 44.988 | 59.952 | 4.941 | 32.801 | 25.941 | 25.327 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 580 | 1.183 | 25.550 | 24.830 | 23.665 |
| Cash | 4.683 | 49.417 | 5.587 | 18.704 | 44.988 | 59.372 | 3.758 | 7.251 | 1.112 | 1.662 |
| Shareholders Funds | 4.592 | 48.797 | 5.022 | 18.449 | 43.267 | 58.666 | 3.909 | 30.997 | 24.940 | 20.640 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 201 | 672 | 565 | 255 | 1.721 | 1.286 | 1.032 | 1.804 | 1.002 | 4.687 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8559 - 8559" | |||||||||
| CAEN Financial Year |
8559
|
|||||||||
Comments - Meditib Ig-Test S.r.l.